<DOC>
	<DOC>NCT00784017</DOC>
	<brief_summary>This multicentric phase III study is designed to assess the efficacy and safety of recombinant asparaginase (rASNase) in comparison to Asparaginase medac™ during treatment of children with de novo ALL</brief_summary>
	<brief_title>Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Previously untreated Tlineage or precursor Blineage ALL Patients must have morphological proof of ALL and diagnosis must be made from bone marrow morphology with more than 25% blasts Written informed consent Treatment according to DCOG ALL 10 protocol Mature Blineage ALL Patients with secondary ALL Known allergy to any ASNase preparation General health status according to Karnofsky / Lansky score &lt; 40% Preexisting known coagulopathy (e.g. haemophilia) Preexisting pancreatitis Liver insufficiency (Bilirubin &gt; 50 µmol/L; SGOT/SGPT &gt; 10 x ULN) Other current malignancies Pregnancy (planned or existent), breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Children with previously untreated acute lymphoblastic leukemia</keyword>
</DOC>